Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

181. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis

Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

182. Management of schizophrenia

Management of schizophrenia SIGN 131 • Management of schizophrenia A national clinical guideline March 2013 Evidence Help us to improve SIGN guidelines - click here to complete our survey KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 - Meta-analyses, systematic reviews, or RCTs (...) or omissions corrections will be published in the web version of this document, which is the definitive version at all times. This version can be found on our web site www.sign.ac.uk. This document is produced from elemental chlorine-free material and is sourced from sustainable forests.Scottish Intercollegiate Guidelines Network Management of schizophrenia A national clinical guideline March 2013Scottish Intercollegiate Guidelines Network Gyle Square, 1 South Gyle Crescent Edinburgh EH12 9EBA

2013 SIGN

183. Cross-sectional study: In individuals with schizophrenia, duration and severity of mental illness, health status, mutuality, employment and household income influence quality of life

Cross-sectional study: In individuals with schizophrenia, duration and severity of mental illness, health status, mutuality, employment and household income influence quality of life In individuals with schizophrenia, duration and severity of mental illness, health status, mutuality, employment and household income influence quality of life | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via (...) your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In individuals with schizophrenia, duration

2013 Evidence-Based Nursing

184. Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population Full Text available with Trip Pro

Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Violent victimisation is more common among people with schizophrenia-spectrum disorders than among the general population Article Text Prevalence

2013 Evidence-Based Mental Health

185. The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age

The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The risk of substance-induced psychosis converting to schizophrenia varies with substance used and patient age Article Text Prognosis The risk of substance-induced

2013 Evidence-Based Mental Health

186. Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)

Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286) Overview | Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) | Guidance | NICE Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) Technology (...) appraisal [TA286] Published date: 22 May 2013 Share Guidance NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder because no evidence submission was received from the manufacturer of the technology. Explore © NICE [year]. All rights reserved. Subject to .

2013 National Institute for Health and Clinical Excellence - Technology Appraisals

187. Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia

Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia Article Text Medical comorbidity Current use of second-generation

2013 Evidence-Based Mental Health

188. Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia

Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) technology-delivered support and education compared with standard care in people with schizophrenia Article Text Therapeutics Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia Statistics from Altmetric.com Question Question: How effective are information and communication technologies (ICT) in delivering psychoeducational interventions to people with schizophrenia and related disorders? Outcomes

2013 Evidence-Based Mental Health

189. Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice

Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice Article Text Prognosis Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice Statistics from Altmetric.com Question Question: What is the effectiveness and cost of atypical versus typical antipsychotic treatment in people with schizophrenia in real practice? Population: A total of 8610 adults (mean

2013 Evidence-Based Mental Health

190. Death rate in older people with schizophrenia elevated compared with the general population

Death rate in older people with schizophrenia elevated compared with the general population Death rate in older people with schizophrenia elevated compared with the general population | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Death rate in older people with schizophrenia elevated compared with the general population Article Text Prognosis Death rate in older people with schizophrenia elevated compared with the general population Statistics

2013 Evidence-Based Mental Health

191. Schizophrenia (revised)

, JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY 976 www.jaacap.org VOLUME 52 NUMBER 9 SEPTEMBER 2013adjusted to work in the PubMed database): aka- thisia OR neuroleptic OR neuroleptics OR neuro- leptic* OR parkinsonian* OR psychoses OR psychotic OR psychosis OR schizoaffective OR schizophren* OR tardive OR “childhood onset schizophrenia”OR“earlyonsetschizophrenia”OR ((chronic OR paranoid) AND schizophren*) OR “Akathisia, Drug-Induced” [MeSH] OR “Dyski- nesia, Drug-Induced” [MeSH (...) Schizophrenia (revised) AACAP OFFICIAL ACTION Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia Jon McClellan, M.D., Saundra Stock, M.D., ANDthe American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI) This Practice Parameter reviews the literature on the assessment and treatment of children and adolescentswithschizophrenia.Early-onsetschizophreniaisdiagnosedusingthesamecriteriaasin

2013 American Academy of Child and Adolescent Psychiatry

192. Psychosis and schizophrenia in children and young people: recognition and management

Psychosis and schizophrenia in children and young people: recognition and management Psy Psychosis and schizophrenia in children chosis and schizophrenia in children and y and young people: recognition and oung people: recognition and management management Clinical guideline Published: 23 January 2013 nice.org.uk/guidance/cg155 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psychosis and schizophrenia in children and young people: recognition and management (CG155) © NICE 2019. All rights reserved. Subject

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

193. Schizophrenia: omega-3 fatty acid medicines

. Schizophrenia Research 49: 243–51 Schizophrenia: omega-3 fatty acid medicines (ESUOM19) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 21 of 27Peet M, Horrobin DF (2002) A dose-ranging exploratory study of the effects of ethyl- eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research 36: 7–18 Politi P , Rocchetti M, Emanuele E et al. (2013) Randomized placebo-controlled trials (...) Schizophrenia: omega-3 fatty acid medicines Schizophrenia: omega-3 fatty acid medicines Schizophrenia: omega-3 fatty acid medicines Evidence summary Published: 24 September 2013 nice.org.uk/guidance/esuom19 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in September 2013. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date

2013 National Institute for Health and Clinical Excellence - Advice

194. Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics Full Text available with Trip Pro

Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added

2013 Evidence-Based Mental Health

195. Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia

Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia Article Text Therapeutics Long-acting risperidone increases medication

2013 Evidence-Based Mental Health

196. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

197. Flupenthixol versus placebo for schizophrenia. (Abstract)

Flupenthixol versus placebo for schizophrenia. Flupenthixol, first made available in the UK in 1965, has been used as a treatment for schizophrenia for decades.To evaluate the absolute clinical effects of flupenthixol for schizophrenia in comparison with placebo.We searched the Cochrane Schizophrenia Group Trials Register (August 2011), inspected references of all included or excluded studies for further trials, and contacted authors of trials for additional information.All randomised (...) controlled trials (RCTs) that compared flupenthixol with placebo for adults with schizophrenia or related disorders by any means of diagnosis. Primary outcomes of interest were clinically important change in global state, mental state and behaviour, and adverse effects.We extracted data from the one included study, discussed any disagreement, documented decisions and contacted the authors of the included study for further information. We analysed binary outcomes using a standard estimation of the risk

2012 Cochrane

198. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia (Abstract)

Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia Some 25%–30% of patients with schizophrenia have auditory verbal hallucinations that are refractory to antipsychotic drugs. Outcomes in studies of repetitive transcranial magnetic stimulation suggest the possibility that application of transcranial direct-current stimulation (tDCS) with inhibitory stimulation over the left temporo-parietal cortex and excitatory stimulation over the left (...) dorsolateral prefrontal cortex could affect hallucinations and negative symptoms, respectively. The authors investigated the efficacy of tDCS in reducing the severity of auditory verbal hallucinations as well as negative symptoms.Thirty patients with schizophrenia and medication-refractory auditory verbal hallucinations were randomly allocated to receive 20 minutes of active 2-mA tDCS or sham stimulation twice a day on 5 consecutive weekdays. The anode was placed over the left dorsolateral prefrontal

2012 EvidenceUpdates Controlled trial quality: uncertain

199. Bitopertin for schizophrenia: primary, persistent negative symptoms sub-optimally controlled positive symptoms ? in combination with antipsychotics

Bitopertin for schizophrenia: primary, persistent negative symptoms sub-optimally controlled positive symptoms ? in combination with antipsychotics Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics NIHR HSC Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antipsychotic

2012 Health Technology Assessment (HTA) Database.

200. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Full Text available with Trip Pro

Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective of the study was to assess the cost-effectiveness of olanzapine and ziprasidone in the treatment of schizophrenia in USA. The authors concluded that olanzapine was associated with better health outcomes

2012 NHS Economic Evaluation Database.